Efficacy of Western, Eastern, and Venezuelan Equine Encephalitis (WEVEE) Virus-Replicon Particle (VRP) Vaccine against WEEV in a Non-Human Primate Animal Model.
Venezuelan equine encephalitis
alphavirus
eastern equine encephalitis
multi-agent vaccination
nonhuman primates
virus replicon particle
western equine encephalitis
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
08 07 2022
08 07 2022
Historique:
received:
16
05
2022
revised:
27
06
2022
accepted:
06
07
2022
entrez:
27
7
2022
pubmed:
28
7
2022
medline:
29
7
2022
Statut:
epublish
Résumé
The purpose of this study was to evaluate the effects of the route of administration on the immunogenicity and efficacy of a combined western, eastern, and Venezuelan equine encephalitis (WEVEE) virus-like replicon particle (VRP) vaccine in cynomolgus macaques. The vaccine consisted of equal amounts of WEEV, EEEV, and VEEV VRPs. Thirty-three animals were randomly assigned to five treatment or control groups. Animals were vaccinated with two doses of WEVEE VRPs or the control 28 days apart. Blood was collected 28 days following primary vaccination and 21 days following boost vaccination for analysis of the immune response to the WEVEE VRP vaccine. NHPs were challenged by aerosol 28 or 29 days following second vaccination with WEEV CBA87. Vaccination with two doses of WEVEE VRP was immunogenic and resulted in neutralizing antibody responses specific for VEEV, EEEV and WEEV. None of the vaccinated animals met euthanasia criteria following aerosol exposure to WEEV CBA87. However, one NHP control (total of 11 controls) met euthanasia criteria after infection with WEEV CBA87. Statistically significant differences in median fever hours were noted in control NHPs compared to vaccinated NHPs, providing a quantitative measure of infection and efficacy of the vaccine against a WEEV challenge. Alterations in lymphocytes, monocytes, and neutrophils were observed. Lymphopenia was observed in control NHPs.
Identifiants
pubmed: 35891482
pii: v14071502
doi: 10.3390/v14071502
pmc: PMC9321360
pii:
doi:
Substances chimiques
Aerosols
0
Antibodies, Viral
0
Viral Vaccines
0
Types de publication
Journal Article
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Références
Can J Public Health. 1952 May;43(5):212-20
pubmed: 14935930
Vaccine. 2006 Mar 20;24(13):2395-402
pubmed: 16406171
J Virol. 2014 Oct;88(20):12077-86
pubmed: 25122801
Tex State J Med. 1946 Jan;41:455-8
pubmed: 21009003
J Am Vet Med Assoc. 1952 Sep;121(906):164-5
pubmed: 13022455
Vaccine. 2009 Aug 6;27(36):4879-82
pubmed: 19576665
J Toxicol Pathol. 2012 Mar;25(1):63-101
pubmed: 22481861
Emerg Infect Dis. 2011 May;17(5):952-4
pubmed: 21529429
Front Immunol. 2021 Jan 19;11:598847
pubmed: 33542715
Sci Transl Med. 2019 May 15;11(492):
pubmed: 31092692
BMC Med. 2009 Apr 14;7:16
pubmed: 19366435
Immunology. 2020 Jun;160(2):116-125
pubmed: 31709535
J Gen Virol. 2006 Aug;87(Pt 8):2353-2361
pubmed: 16847131
J Infect Dis. 2005 Oct 1;192(7):1173-82
pubmed: 16136459
Virology. 1997 Dec 22;239(2):389-401
pubmed: 9434729
Scand J Infect Dis. 1987;19(6):617-21
pubmed: 3441747
J Infect Dis. 1998 Mar;177(3):634-41
pubmed: 9498442
Adv Drug Deliv Rev. 2005 Jun 17;57(9):1293-314
pubmed: 15935875
Toxicol Pathol. 2015 Jun;43(4):513-8
pubmed: 24935239
Vaccine. 1996 Aug;14(12):1132-6
pubmed: 8911009
Pharm Res. 2016 Sep;33(9):2078-97
pubmed: 27380191
Vaccine. 2016 Apr 12;34(17):2027-34
pubmed: 26768126
Science. 1967 Dec 8;158(3806):1283-6
pubmed: 6058003